ClinicalTrials.gg
RecruitingNCT03584204SLIMUpdated Oct 5, 2021

Skeletal Muscle Parameters of Liver Cirrhosis in Non-invasive Imaging and Outcome

An observational study in Liver Cirrhosis, sponsored by University Hospital, Bonn. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-10-05.

Sponsored by University Hospital, Bonn · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2018; still recruiting 8 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
400
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Liver Cirrhosis with a site in Germany — 24 open to participants now, 27 under way, 2 of them phase 3. Liver Cirrhosis · Germany.

Planned enrollment
15th of 37
400 · median 200
Started
2018
with 6 others
Observational
37 of 82
15 open now
Primary completion
2025-07
later than 6 of 26 live
Registered
35th of 82
by date

Among the 82 studies in Liver Cirrhosis with a site in Germany, this one is the 15th largest by planned enrollment of the 37 observational ones that give a count, is one of 7 that started in 2018, is one of 37 observational ones, reaches primary completion later than 6 of the 26 other live ones, and was the 35th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

24 of the 82 studies in Liver Cirrhosis with a site in Germany are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Liver Cirrhosis with a site in Germany, or all of them as a file.
02

Study summary

The principal aim of this study is to analyse L3-SMI (skeletal muscle index) in a cohort of patients with decompensated liver cirrhosis and TIPS (transjugular intrahepatic portosystemic shunt), and compare the prognostic power with TPMT (transverse psoas muscle thickness). Furthermore, the role of myosteatosis, determined in CT by L3-SMI, MRI and ultrasound will be studied.

Read the detailed description

The principal aim of this study is to analyse L3-SMI (skeletal muscle index) in a cohort of patients with decompensated liver cirrhosis and TIPS (transjugular intrahepatic portosystemic shunt), and compare the prognostic power with TPMT (transverse psoas muscle thickness). Furthermore, the role of myosteatosis, determined in CT by L3-SMI, MRI and ultrasound will be studied.

03

Conditions studied

  • Liver Cirrhosis

Keywords

  • sarcopenia
  • cirrhosis
  • transjugular intrahepatic portosystemic shunt
  • TIPS
  • acute-on-chronic liver failure
  • ACLF
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with liver cirrhosis of any etiology and CT scan available

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • liver cirrhosis of any etiology
  • CT scan available

Exclusion criteria

Exclusion Criteria:

  • HCC or any malignant disease
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
400 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testimaging

    computed tomography, magnetic resosnance imaging, ultrasound

06

What researchers measure

Primary outcomes

  1. Survival time

    time of survival

    Time frame: up to 60 months

Secondary outcomes

  1. Time to clinical acute decompensations

    time to occurrence of acute decompensations of liver cirrhosis (readmissions, hepatic encephalopathy, bleeding, ascites, hepatorenal syndrome, infections)

    Time frame: up to 60 months

  2. Time to clinical acute-on-chronic liver failure

    acute-on-chronic liver failure according to EASL-CLIF-C definition (grade 1 (best) to 3 (worst)

    Time frame: up to 60 months

  3. Development of sarcopenia

    Assessment of sarcopenia according to EASL-guideline

    Time frame: up to 60 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Faron A, Abu-Omar J, Chang J, Bohling N, Sprinkart AM, Attenberger U, Rockstroh JK, Luu AM, Jansen C, Strassburg CP, Trebicka J, Luetkens J, Praktiknjo M. Combination of Fat-Free Muscle Index and Total Spontaneous Portosystemic Shunt Area Identifies High-Risk Cirrhosis Patients. Front Med (Lausanne). 2022 Apr 12;9:831005. doi: 10.3389/fmed.2022.831005. eCollection 2022. PubMed 35492329 ↗
  • Queck A, Thomas D, Jansen C, Schreiber Y, Ruschenbaum S, Praktiknjo M, Schwarzkopf KM, Mucke MM, Schierwagen R, Uschner FE, Meyer C, Claria J, Zeuzem S, Geisslinger G, Trebicka J, Lange CM. Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. PLoS One. 2019 Oct 23;14(10):e0222840. doi: 10.1371/journal.pone.0222840. eCollection 2019. PubMed 31644538 ↗
  • Praktiknjo M, Clees C, Pigliacelli A, Fischer S, Jansen C, Lehmann J, Pohlmann A, Lattanzi B, Krabbe VK, Strassburg CP, Arroyo V, Merli M, Meyer C, Trebicka J. Sarcopenia Is Associated With Development of Acute-on-Chronic Liver Failure in Decompensated Liver Cirrhosis Receiving Transjugular Intrahepatic Portosystemic Shunt. Clin Transl Gastroenterol. 2019 Apr;10(4):e00025. doi: 10.14309/ctg.0000000000000025. PubMed 30939488 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2018 (actual). Primary completion is estimated for Jul 2025, 90 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2018
First posted
Jul 12, 2018
StartActual
Jan 1, 2018
Primary completionEst.
Jul 31, 2025
CompletionEst.
Aug 31, 2026
Last update
Oct 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03584204
Responsible party
Michael Praktiknjo (Principal Investigator, University Hospital, Bonn) — Principal investigator
First posted
Jul 12, 2018
Start date
Jan 1, 2018
Primary completion
Jul 31, 2025 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Oct 5, 2021

Study contacts

Michael Praktiknjo, MD
Contact
michael.praktiknjo@ukbonn.de
+49228 287 15770
Johannes Chang, MD
Contact
johannes.chang@ukbonn.de
+49228 287 15770
Michael Praktiknjo, MD
principal investigator · University Hospital, Bonn

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion